Previous 10 | Next 10 |
This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...
Agenus (NASDAQ:AGEN) and Targovax ASA signed a clinical collaboration and supply agreement to combine Targovax’s TG mutant KRAS cancer vaccines with Agenus' QS-21 STIMULON adjuvant technology. Agenus said TG01 has shown promise in phase 1/2 trials, and Targovax was recently awarde...
The parties have entered into a collaboration agreement to develop Targovax´s TG mutant KRAS cancer vaccines in combination with Agenus´s QS-21 STIMULON adjuvant technology The agreement may be extended into an exclusive commercial partnership for KRAS vaccination if the c...
Shares of clinical-stage immunotherapy company Agenus (NASDAQ: AGEN) were up by a healthy 18% as of 1:09 p.m. ET on Wednesday. Investors are bidding up the biotech's stock today following the release of its 2021 fourth-quarter and full-year earnings report. What appears to r...
The following slide deck was published by Agenus Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Agenus Inc. 2021 Q4 - Results - Earnings Call Presentation
Image source: The Motley Fool. Agenus (NASDAQ: AGEN) Q4 2021 Earnings Call Mar 01, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Agenus (AGEN) Q4 2021 Earnings Call Transcript
Agenus Inc. (AGEN) Q4 2021 Earnings Conference Call March 01, 2022 8:30 AM ET Company Participants Divya Vasudevan – Senior Director, Oncology Strategy and Investor Relations Garo Armen – Chairman and Chief Executive Officer Steven O'Day – Chief Medical Officer Chandresh ...
Agenus press release (NASDAQ:AGEN): Q4 GAAP EPS of -$0.26 misses by $0.10. Revenue of $20.26M (-35.2% Y/Y) misses by $17.48M. Shares +1.85% PM. For further details see: Agenus GAAP EPS of -$0.26 misses by $0.10, revenue of $20.26M misses by $17.48M
Botensilimab (Fc-enhanced) is the first anti-CTLA-4 antibody to demonstrate clinical responses across 9 cold, treatment-resistant cancers; Phase II studies planned in melanoma, MSS-colorectal, and pancreatic cancers AGEN1571, a novel program targeting tumor-associated macrophages, is ...
Agenus (NASDAQ:AGEN) is scheduled to announce Q4 earnings results on Tuesday, Mar. 1, before market open. The consensus EPS estimate is -$0.16 and the consensus revenue estimate is $37.74M (+20.7% Y/Y). Over the last 1 year, AGEN has beaten EPS estimates 63% of the time and has beaten revenue...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...